Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one

resiquimod has been researched along with 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one in 1 studies

Compound Research Comparison

Studies
(resiquimod)		Trials
(resiquimod)		Recent Studies (post-2010)
(resiquimod)		Studies
(5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one)		Trials
(5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one)		Recent Studies (post-2010) (5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one)
465143181820145

Protein Interaction Comparison

ProteinTaxonomyresiquimod (IC50)5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one (IC50)
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)1.48

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

1 other study(ies) available for resiquimod and 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023